N-(4-isopropoxypyridin-3-yl)-2-phenylimidazo[1,2-b]pyridazine-8-carboxamide

ID: ALA5290040

Max Phase: Preclinical

Molecular Formula: C21H19N5O2

Molecular Weight: 373.42

Names and Identifiers

Canonical SMILES:  CC(C)Oc1ccncc1NC(=O)c1ccnn2cc(-c3ccccc3)nc12

Standard InChI:  InChI=1S/C21H19N5O2/c1-14(2)28-19-9-10-22-12-17(19)25-21(27)16-8-11-23-26-13-18(24-20(16)26)15-6-4-3-5-7-15/h3-14H,1-2H3,(H,25,27)

Standard InChI Key:  GSXIRUIKNXNLAP-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 28 31  0  0  0  0  0  0  0  0999 V2000
    0.6274    1.0248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0835    1.4431    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0835    2.2797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7947    1.0248    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5059    1.4431    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2588    1.0248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2588    0.2300    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5059   -0.1882    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7947    0.2300    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5059   -1.0248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2588   -1.4431    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2588   -2.2797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5059   -2.6980    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7947   -2.2797    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000   -2.5307    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4601   -1.8614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000   -1.1921    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7947   -1.4431    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2967   -1.8614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7150   -1.1503    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5516   -1.1503    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9699   -1.8614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5516   -2.5726    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7150   -2.5726    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9699    1.4431    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9699    2.2797    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2588    2.6980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5059    2.2797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  1  0
  4  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 10 18  1  0
 14 18  1  0
 16 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 19 24  1  0
  6 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
  5 28  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5290040

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 373.42

Molecular Weight (Monoisotopic): 373.1539

AlogP: 3.83

#Rotatable Bonds: 5

Polar Surface Area: 81.41

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 5.82

CX LogP: 3.18

CX LogD: 3.17

Aromatic Rings: 4

Heavy Atoms: 28

QED Weighted: 0.57

Np Likeness Score: -1.81

References

1. Hartz RA, Ahuja VT, Sivaprakasam P, Xiao H, Krause CM, Clarke WJ, Kish K, Lewis H, Szapiel N, Ravirala R, Mutalik S, Nakmode D, Shah D, Burton CR, Macor JE, Dubowchik GM..  (2023)  Design, Structure-Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-b]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors.,  66  (6): [PMID:36950863] [10.1021/acs.jmedchem.3c00133]

Source

Source(1):

• Scientific Literature